This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Cisco Systems, Caterpillar, Charles Schwab and Elite Pharmaceuticals
by Zacks Equity Research
CSCO, CAT, SCHW and ELTP are driving gains with strong segment growth, strategic deals, and rising investor interest in key sectors.
Top Analyst Reports for Cisco, Caterpillar & Charles Schwab
by Mark Vickery
CSCO, CAT and SCHW shares outperformed peers as analysts highlight growth drivers and risks in key business segments.
Elite Pharmaceuticals Stock Dips Despite Record FY25 Revenue Jump
by Zacks Equity Research
ELTP posts record fiscal 2025 revenues and operating income gains, fueled by new launches and expanding generics market share.
Zacks Market Edge Highlights: Elite Pharmaceuticals and Frequency Electronics
by Zacks Equity Research
Elite Pharmaceuticals and Frequency Electronics are part of the Zacks Market Edge blog.
2 Defensive American Small Cap Stocks for 2025
by Tracey Ryniec
Tracey Ryniec, Zacks Senior Stock Strategist, and Mark Zinski, Zacks Senior Microcap Research Analyst, discuss two of Mark's top defensive small cap stocks in an uncertain world.
The Zacks Analyst Blog Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research
by Zacks Equity Research
Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research are included in this Analyst Blog.
Top Stock Reports for Philip Morris, Booking Holdings & Anheuser-Busch
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Philip Morris International Inc. (PM), Booking Holdings Inc. (BKNG) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Elite Pharmaceuticals, Inc. (ELTP) and National Research Corp. (NRC).
ELTP Stock Falls Following Q3 Earnings Decline, Revenue Down Y/Y
by Zacks Equity Research
Elite Pharmaceuticals' third-quarter fiscal 2025 reports a revenue drop and a net loss. However, delayed shipments impact results.
The Zacks Analyst Blog Costco, T-Mobile US, Uber Technologies, SandRidge and Elite Pharmaceuticals
by Zacks Equity Research
Costco, T-Mobile US, Uber Technologies, SandRidge and Elite Pharmaceuticals are included in this Analyst Blog.
Two Smaller Companies Worthy of Your "Attention"
by Mark Zinski
Here we highlight a small cap and a microcap with Zacks Outperform ratings.
Elite Pharmaceuticals' Stock Up Despite Q2 Earnings Decline
by Zacks Equity Research
ELTP sees strong revenue growth despite a net loss, driven by new product launches and strategic acquisitions.
The Zacks Analyst Blog Highlights NVIDIA, American Express, Wells Fargo, Elite Pharmaceuticals and PrimeEnergy
by Zacks Equity Research
NVIDIA, American Express, Wells Fargo, Elite Pharmaceuticals and PrimeEnergy are included in this Analyst Blog.
Top Analyst Reports for NVIDIA, American Express & Wells Fargo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), American Express Company (AXP) and Wells Fargo & Company (WFC), as well as two micro-cap stocks Elite Pharmaceuticals, Inc. (ELTP) and PrimeEnergy Resources Corporation (PNRG).
Elite Pharmaceuticals (ELTP) Posts Breakeven Q1 Earnings
by Zacks Equity Research
Strength in Elite Pharmaceuticals' (ELTP) Manufacturing fees drive its fiscal first-quarter performance.
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
by Zacks Equity Research
Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri are part of the Zacks top Analyst Blog.
Zacks Initiates Coverage of Elite Pharmaceuticals With Outperform Recommendation
by Debanjana Dey
Discover why Zacks rates Elite Pharmaceuticals as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore ELTP's strategic partnerships, financial health, and robust product pipeline.
Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down
by Zacks Equity Research
Elite Pharmaceuticals' (ELTP) overall top line benefits from revenue growth in Manufacturing fees.